HK1065722A1 - Cpg plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein d cpg 1 d - Google Patents

Cpg plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein d cpg 1 d

Info

Publication number
HK1065722A1
HK1065722A1 HK04108725.1A HK04108725A HK1065722A1 HK 1065722 A1 HK1065722 A1 HK 1065722A1 HK 04108725 A HK04108725 A HK 04108725A HK 1065722 A1 HK1065722 A1 HK 1065722A1
Authority
HK
Hong Kong
Prior art keywords
cpg
glycoprotein
water emulsion
adjuvant system
bovine herpesvirus
Prior art date
Application number
HK04108725.1A
Other languages
English (en)
Chinese (zh)
Inventor
Lorne Alan Babiuk
Rolf Hecker
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of HK1065722A1 publication Critical patent/HK1065722A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK04108725.1A 2001-10-06 2004-11-05 Cpg plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein d cpg 1 d HK1065722A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32773401P 2001-10-06 2001-10-06
PCT/EP2002/011206 WO2003030934A2 (fr) 2001-10-06 2002-10-07 Formulations cpg et procedes y relatifs

Publications (1)

Publication Number Publication Date
HK1065722A1 true HK1065722A1 (en) 2005-03-04

Family

ID=23277807

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04108725.1A HK1065722A1 (en) 2001-10-06 2004-11-05 Cpg plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein d cpg 1 d

Country Status (9)

Country Link
US (1) US20050238660A1 (fr)
EP (1) EP1434602B1 (fr)
JP (1) JP2005508945A (fr)
KR (1) KR20050048539A (fr)
CN (1) CN100438908C (fr)
AU (1) AU2002347062B2 (fr)
CA (1) CA2471968C (fr)
HK (1) HK1065722A1 (fr)
WO (1) WO2003030934A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1077722B1 (fr) 1998-05-22 2006-08-09 Ottawa Health Research Institute Methodes et produits permettant d'induire une immunite au niveau des muqueuses
DK1104306T3 (da) * 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
WO2004087203A2 (fr) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Formulations de type huile-dans-l'eau a base d'acides nucleiques immunostimulateurs, et procedes d'utilisation associes
JP4629964B2 (ja) * 2003-09-12 2011-02-09 株式会社林原生物化学研究所 ウシの消化器疾患治療剤
US8148341B2 (en) * 2005-07-01 2012-04-03 Index Pharmaceuticals Ab Method for modulating responsiveness to steroids
ES2349617T3 (es) * 2005-07-01 2011-01-07 Index Pharmaceuticals Ab Método inmunoestimulante.
JP2009513629A (ja) * 2005-10-28 2009-04-02 インデックス・ファーマシューティカルズ・アクチエボラーグ 炎症性疾患を予防、処置、および／または緩和する組成物および方法
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
JP2010525063A (ja) * 2007-04-27 2010-07-22 キメリクス，インコーポレイテッド ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
WO2009011897A1 (fr) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinaisons pour le traitement des troubles prolifératifs des lymphocytes b
CN105055432A (zh) 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
CN101559224B (zh) * 2008-04-18 2012-07-11 北京生物制品研究所 脊髓灰质炎疫苗
CA2725381A1 (fr) * 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Adjuvants de nanoemulsion
US9415006B2 (en) * 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
WO2009151569A2 (fr) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Agonistes des récepteurs bêta-adrénergiques utilisables pour le traitement des troubles prolifératifs des lymphocytes b
WO2009156960A2 (fr) 2008-06-27 2009-12-30 Pfizer Inc. Nouvelles compositions d'adjuvants
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
EP2687209A1 (fr) 2008-09-19 2014-01-22 Nestec S.A. Soutien nutritionnel pour prévenir et/ou atténuer la toxicité sur la moelle osseuse due à une tumeur cancéreuse
CN102164595A (zh) * 2008-09-19 2011-08-24 雀巢产品技术援助有限公司 抗癌治疗中的免疫系统营养支持
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
WO2010043039A1 (fr) 2008-10-16 2010-04-22 University Of Saskatchewan Formulation d’adjuvant de combinaison
US8394384B2 (en) 2008-11-28 2013-03-12 Merial Limited Recombinant avian influenza vaccine and uses thereof
EP2442827B1 (fr) 2009-06-16 2016-01-06 The Regents of the University of Michigan Vaccins en nano-émulsion
EP3216789A1 (fr) 2010-02-12 2017-09-13 Chimerix, Inc. Procédés de traitement d'une infection virale
US20110229512A1 (en) * 2010-03-19 2011-09-22 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
EP2563367A4 (fr) 2010-04-26 2013-12-04 Chimerix Inc Méthodes de traitement d'infections rétrovirales et régimes posologiques associés
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
BR112015009229B1 (pt) 2012-10-24 2021-07-20 Platelet Targeted Therapeutics, Llc Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
CN103127501A (zh) * 2013-03-27 2013-06-05 南京农业大学 一种用于鸡禽流感鼻腔免疫的人工合成佐剂
JP6586083B2 (ja) 2013-09-19 2019-10-02 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
CA2928700C (fr) 2013-11-01 2019-01-15 University Of Oslo Variants d'albumine et utilisations de ceux-ci
CA2929126C (fr) 2013-11-13 2020-01-07 University Of Oslo Vesicules de membrane externe et utilisation associees
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
JP7158853B2 (ja) 2014-10-10 2022-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物
KR20170097116A (ko) 2015-01-16 2017-08-25 조에티스 서비시즈 엘엘씨 구제역 백신
EP4226936A3 (fr) 2015-03-05 2023-09-27 Northwestern University Virus non neuro-invasifs et leurs utilisations
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
TN2018000301A1 (en) 2016-03-14 2020-01-16 Univ Oslo Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (fr) 2016-03-14 2017-09-21 University Of Oslo Immunoglobulines anti-virales synthétiques
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
WO2017221072A2 (fr) 2016-06-21 2017-12-28 University Of Oslo Fragments de vaccin de liaison à hla et leurs utilisations
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
WO2019048928A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules de vaccin
CN110218729B (zh) * 2019-05-07 2023-06-20 华南农业大学 一种鸡特异性免疫活化剂CpG-ODN及其应用
US20240156935A1 (en) 2021-03-31 2024-05-16 Vib Vzw Vaccine Compositions for Trypanosomatids
EP4108771A1 (fr) * 2021-06-24 2022-12-28 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Oligonucléotides contenant un quadruplex g pour le traitement préventif et thérapeutique
CN114469913B (zh) * 2022-02-17 2024-03-22 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Tilorone用于预防/治疗非洲猪瘟病毒感染的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4973307A (en) 1981-07-13 1990-11-27 Alza Corporation Method for administering drugs to a patient
US5250028A (en) 1989-02-15 1993-10-05 Alza Corporation Intravenous system for delivering a beneficial agent using permeability enhancers
US6656477B1 (en) * 1992-07-28 2003-12-02 Board Of Trustees Of Michigan State University 43 Kd protein vaccine and method for the production thereof
US5951988A (en) * 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1005368B1 (fr) * 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Utilisation d'acides nucléiques contenat un dinucléotide CpG non-methylé combiné avec de l'aluminium en tant qu'adjuvants
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998040097A2 (fr) * 1997-03-10 1998-09-17 Bayer Corporation Coronavirus respiratoire bovin utilise comme vaccin
HUP0101047A3 (en) * 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
JP2003524586A (ja) * 1998-05-21 2003-08-19 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの非−非経口投与のための組成物と方法
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
EP2286792A1 (fr) * 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions avec une surface adsorbante, comprenant une émulsion de microgouttes
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
DK1187629T3 (da) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases

Also Published As

Publication number Publication date
EP1434602A2 (fr) 2004-07-07
CN1671414A (zh) 2005-09-21
WO2003030934A2 (fr) 2003-04-17
WO2003030934A3 (fr) 2003-11-06
KR20050048539A (ko) 2005-05-24
EP1434602B1 (fr) 2014-12-17
CA2471968C (fr) 2013-07-23
CA2471968A1 (fr) 2003-04-17
US20050238660A1 (en) 2005-10-27
JP2005508945A (ja) 2005-04-07
CN100438908C (zh) 2008-12-03
AU2002347062B2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
HK1065722A1 (en) Cpg plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein d cpg 1 d
EG22812A (en) Depwater intervention system
PL337488A1 (en) Oil-in-water type compositions for vaccines
SG96620A1 (en) Health maintenance system
IL146174A0 (en) Confocal wafer-inspection system
GR3034300T3 (en) Iso-tridecanolalkoxylates in block form as low-foam or antifoaming surfactants
EP0985044A4 (fr) Vaccin anticancereux
GB0016196D0 (en) Oil system
GB2367471B (en) Graphics system
GB0027724D0 (en) "System"
PL359848A1 (en) Composition suitable for preparing an oil in water emulsion
HK1055604A1 (en) Surfactant system
GB0116652D0 (en) De-icing system
GB2375721B (en) Water conditioning system
GB2361137B (en) Scanning system
GB0107144D0 (en) Water circulation system
AU2002343509A8 (en) Debris removal system
GB9724962D0 (en) Improvements in or relating to document platforms
GB0122483D0 (en) High level maintenance safety system
GB2360838B (en) Cooling system expansion tank
AU7451801A (en) Account settling system
GB2379634B (en) Greetings card support
GB0017250D0 (en) Flooring system
GB0012292D0 (en) Improvements in or relating to command systems
GB0109376D0 (en) Waste water heat recovery system

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20221010